Theresa Link

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Sibylle Loibl, Jens Huober, Michael Braun et al. · Annals of Oncology · 2022 · 244 citations

Medicine, Oncology, Breast Oncology +9

Impact of breast cancer subtypes and patterns of metastasis on outcome

Karin Kast, Theresa Link, Katrin Friedrich et al. · Breast Cancer Research and Treatment · 2015 · 222 citations

Medicine, Oncology, Surgery +12

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Peter A. Fasching, Theresa Link, Jan Hauke et al. · Annals of Oncology · 2020 · 144 citations · Full text

Medicine, Cancer Biology, Oncology +17

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Sibylle Loibl, Andreas Schneeweiß, Jens Huober et al. · Journal of Clinical Oncology · 2021 · 118 citations

Medicine, Oncology, Pharmacology +17